Last reviewed · How we verify
Intraoperative anesthetic strategy by Desflurane
GABA receptor antagonist
GABA receptor antagonist Used for General anesthesia.
At a glance
| Generic name | Intraoperative anesthetic strategy by Desflurane |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | General anesthetic |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 2 |
Mechanism of action
Desflurane acts as a non-competitive antagonist of the GABA_A receptor, leading to an increase in neuronal excitability and a decrease in inhibitory neurotransmission.
Approved indications
- General anesthesia
Common side effects
- Respiratory depression
- Hypotension
- Nausea and vomiting
Key clinical trials
- Desflurane vs. Propofol for Cardiac Anesthesia (PHASE3)
- Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring - COGNIDES (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: